Search Result

Results for "

retinal degeneration

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Bacterial (1) Biochemical Assay Reagents (1) Endogenous Metabolite (5) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (1) HSP (1) iGluR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) MyD88 (1) NF-κB (1) Orphan Receptor (1) Ras (1) Trk Receptor (1) VEGFR (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116098

Anecortave desacetate AL-4940	Biochemical Assay Reagents	Cancer
Anecortave desacetate (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .

HY-124717

YC-001	Endogenous Metabolite	Others
YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-101446

HIOC	Trk Receptor ERK Apoptosis	Neurological Disease
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-N7270

Apigenin-7-diglucuronide	Others	Inflammation/Immunology
Apigenin-7-diglucuronide is a flavonoid glycoside and is present in an assortment of medicinal plants with anti-inflammatory or ant-oxidant activities. Apigenin-7-diglucuronide protects retinas against bright light-induced photoreceptor degeneration through the inhibition of retinal oxidative stress and inflammation .

HY-109869

Photoregulin1	Orphan Receptor	Others
Photoregulin1 is a compound with the potential to inhibit retinitis pigmentosa that modulates gene expression in retinal cells and slows the degeneration of photoreceptors in a mouse model.

HY-113127

L-Tryptophanamide	Apoptosis	Others
L-Tryptophanamide is a compound discovered in wet age-related macular degeneration research, which has activities related to affecting retinal cell proliferation, apoptosis, necrosis and angiogenesis. In in vitro experiments, L-Tryptophanamide affects the proliferation, apoptosis and necrosis of human retinal pigment epithelial cells, and promotes tube formation and migration of human retinal endothelial cells.

HY-136234

9-cis-β-Carotene	Endogenous Metabolite	Others
9-cis-β-Carotene, a precursor of retinal, is cleaved by beta-carotene oxygenase 1 (BCMO1) to produce 9-cis-retinal. 9-cis-β-Carotene inhibits photoreceptor degeneration and restores retinal function in vivo. 9-cis-β-Carotene has the potential for the study of congenital stationary night blindness and fundus albipunctatus .

HY-116312

8-CPT-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-CPT-2'-O-Me-cAMP is a Rap1 activator. 8-CPT-2'-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-N11499

Myricetin 3-O-α-L-arabinopyranoside	Bacterial	Infection Inflammation/Immunology
Myricetin 3-O-α-L-arabinopyranoside is a quercetin derivative and plant flavonoid with antioxidant, antibacterial and antiurease effects. Myricetin 3-O-α-L-arabinopyranoside inhibits A2E photooxidation-induced RPE cell death. Myricetin 3-O-α-L-arabinopyranoside is protective against retinal degeneration and protects against blue light (BL)-induced damage in RPE cells and mouse models .

HY-110195

Smurf1-IN-A01 1 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others Cancer
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-162904

BPU17	Mitochondrial Metabolism	Cardiovascular Disease
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .

HY-122129

Dotriaconta-14,17,20,23,26,29-hexaenoic acid	Endogenous Metabolite	Metabolic Disease
Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina.

HY-122129S

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d₆ is deuterium labeled Dotriaconta-14,17,20,23,26,29-hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina .

HY-14608R

L-Glutamic acid (Standard)	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

Cat. No.	Product Name	Target	Research Area

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-124717

YC-001	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration .

HY-N7270

Apigenin-7-diglucuronide	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology	Others
Apigenin-7-diglucuronide is a flavonoid glycoside and is present in an assortment of medicinal plants with anti-inflammatory or ant-oxidant activities. Apigenin-7-diglucuronide protects retinas against bright light-induced photoreceptor degeneration through the inhibition of retinal oxidative stress and inflammation .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-N11499

Myricetin 3-O-α-L-arabinopyranoside	Structural Classification Flavonoids Flavones Source classification Plants Sapotaceae Pouteria torta (Mart.) Radlk.	Bacterial
Myricetin 3-O-α-L-arabinopyranoside is a quercetin derivative and plant flavonoid with antioxidant, antibacterial and antiurease effects. Myricetin 3-O-α-L-arabinopyranoside inhibits A2E photooxidation-induced RPE cell death. Myricetin 3-O-α-L-arabinopyranoside is protective against retinal degeneration and protects against blue light (BL)-induced damage in RPE cells and mouse models .

Cat. No.	Product Name	Chemical Structure

HY-122129S

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6
Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d₆ is deuterium labeled Dotriaconta-14,17,20,23,26,29-hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina .

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d₆ is deuterium labeled Dotriaconta-14,17,20,23,26,29-hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

retinal degeneration

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products